Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PhRMA Seeks Regulatory Guidance On Primary Prevention Products

This article was originally published in The Pink Sheet Daily

Executive Summary

The trade association also hopes HHS will encourage reimbursement policies that support the effective delivery of prevention products to patients, PhRMA VP-Scientific & Regulatory Affairs Loew says.

You may also be interested in...

FDA, CMS To Begin Collaborating On Drug Safety Data Collection In 2005

HHS Medical Innovation Task Force report says CMS will assist FDA in postmarketing drug surveillance. The collaboration also includes parallel reviews by the two agencies to minimize delays between marketing approval and reimbursement.

Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic

Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts